Item 8.01. Other Events.
On
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. Exhibit No. Description 99.1 Press release titled "BeiGene Provides Regulatory Update on theU.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC" issued byBeiGene, Ltd. onJuly 14, 2022 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL
--------------------------------------------------------------------------------
© Edgar Online, source